ArticleNutrition & metabolism2025
Trends of blood pressure control in metabolic syndrome among US adults: evidence from NHANES 1999 to 2020.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal assessment of metabolic and neurological decline in peripheral polyneuropathy over ten years.Future science OA · 2026Article
- Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic Syndrome (MetS) involves several cardiovascular risk factors, with hypertension being a critical component that significantly impacts cardiovascular outcomes. As guidelines support blood pressure control in populations with high cardiovascular risk factors, we evaluated BP control in MetS patients.
methodsWe conducted a cross-sectional analysis of probability samples of adults aged ≥ 18 years with MetS from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020 to assess changes in BP control. MetS was identified by meeting at least three of the following criteria: (1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women; (2) fasting glucose ≥ 100 mg/dl; (3) BP ≥ 130/85 mmHg; (4) triglycerides ≥ 150 mg/dl; and (5) high-density lipoprotein cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women. BP control was defined as systolic BP < 130 mmHg and diastolic BP < 80 mmHg. All analyses accounted for differences between survey years, complex sampling design, and survey weights.
resultsFrom 1999-2002 to 2015-2020, the prevalence of MetS increased from 19% to 24% (P < 0.001). Among MetS patients, the proportion of those self-reporting hypertension or taking BP medications increased from 65% in 1999-2002 to 72% in 2015-2020 (P = 0.001). Over time, both the use and quantity of antihypertensive medications increased significantly, and according to current guidelines, BP control among MetS patients has improved significantly. Similar trends were observed across subgroups stratified by gender, diabetes status, and CKD status.
conclusionBP management in MetS patients showed significant improvement from 1999 to 2020, with increasing control rates despite fluctuations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.